Search Results

You are looking at 311 - 320 of 2,852 items for :

  • Refine by Access: All x
Clear All
Full access

Management of Patients With Cytogenetically Normal Acute Myeloid Leukemia Who Have Neither Favorable nor Unfavorable Markers

Alison R. Walker and Guido Marcucci

is used to determine outcome risk and direct treatment strategies for patients, including allogeneic stem cell transplantation (SCT) in first complete remission. However, in 40% to 50% of patients, chromosome aberrations are not detected, making it

Full access

HSR20-076: Provider Versus Patient Reported Outcomes (PROs) in Colorectal Cancer (CRC) Patients (pts) Undergoing Systemic Therapy (Ctx): A Real World Experience

Sonali Agrawal, Caitlin R. Meeker, Sandeep Aggarwal, Elizabeth A. Handorf, Sunil Adige, Efrat Dotan, Crystal S. Denlinger, William H. Ward, Jeffrey M. Farma, and Namrata Vijayvergia

Full access

HSR22-163: Real World Data and Independent Predictors of Clinical Outcomes with CDK Inhibitors in Metastatic ER+ Breast Cancer Patients

Priyanka Reddy, James Martin, and Alberto Montero

Full access

Impact of Cumulative Chemotherapy Dose on Survival With Adjuvant FEC-D Chemotherapy for Breast Cancer

Zachary Veitch, Omar F. Khan, Derek Tilley, Patricia A. Tang, Domen Ribnikar, Douglas A. Stewart, Xanthoula Kostaras, Karen King, and Sasha Lupichuk

data, 14 , 15 whereas cyclophosphamide escalation did not lead to improved outcomes. 16 , 17 These results are informative but require updating as CMF, CAF, and FEC are inferior to third-generation chemotherapy regimens currently used in the adjuvant

Full access

The Integration of Chemotherapy and Surgery for Bladder Cancer

Matthew D. Galsky, Harry W. Herr, and Dean F. Bajorin

cancer outcomes after radical cystectomy . Urology 2003 ; 61 : 105 – 108 . 6 Konety BR Joslyn SA O'Donnell MA . Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: Analysis of data from the

Full access

Treatment of Acute Promyelocytic Leukemia for Older Patients

Thomas Prebet and Steven D. Gore

T he treatment of acute myeloid leukemia (AML) in older patients remains challenging. 1 Both disease- and patient-related factors unfavorably influence patient outcome, with a 2-year probability of overall survival of 10% to 15%. 2 Acute

Full access

VATS Versus Open Surgery for Lung Cancer Resection: Moving Toward a Minimally Invasive Approach

Jacob Klapper and Thomas A. D’Amico

. The thoracoscopic approach is oncologically equivalent to thoracotomy, while resulting in fewer complications, improved quality of life, shorter length of stay, and superior compliance with adjuvant therapies. 6 – 8 Oncologic Outcomes The

Full access

Reducing the Time From Initial Call to First Appointment: The Impact of Patient Access Redesign and a Nurse Navigation Program

Lori J. Goldstein, Bonnie J. Miller, Nancy Nicotera, and Delinda Pendleton

, FCCC’s performance has demonstrated a high level of concordance, based on findings from the NCCN Oncology Outcomes Database project benchmarking data in breast cancer. Access to the NCCN Breast Cancer Timing in Continuation and Transition of Care

Full access

Toward Less-Invasive Management of Early-Stage Breast Cancer

Amy Cyr

modality. This modality allows for more individualized, flexible delivery of radiation and appears to result in less fat necrosis; however, formal data on these and oncologic outcomes are lacking. In a study presented at the ASTRO 2014 Annual Meeting, after

Full access

In the Age of Novel Therapies, What Defines High-Risk Multiple Myeloma?

Ashraf Badros

% of patients survive longer than 10 years, irrespective of therapy. 1 , 2 Genetic variations among myeloma cells appear to underlie much of the heterogeneity in clinical outcomes. Several groups have reported on the prognostic capability of genetic